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S U M M A R Y
Objectives: Risk factors for septic shock associated with methicillin-resistant Staphylococcus aureus
(MRSA) bacteremia are not well described. We designed this study to assess the independent predictors
of septic shock in patients with MRSA bacteremia.
Methods: This retrospective chart review included 234 patients with MRSA bacteremia admitted to a
tertiary care academic medical center. Cases of septic shock and non-septic shock MRSA bacteremia
were compared in terms of patient baseline characteristics and co-morbidities, modes of acquisition, and
MRSA genotyping. Independent risk factors were determined by multivariable analysis.
Results: On univariate analysis the presence of chronic kidney disease, respiratory failure, acute renal
failure, staphylococcal cassette chromosome (SCCmec) type II, and higher APACHE II scores were
signiﬁcantly correlated with the presence of septic shock. On multivariate analysis, baseline APACHE II
score (adjusted odds ratio (AOR) for 1-point increase 1.13, 95% conﬁdence interval (CI) 1.04–1.22,
p = 0.005), acute renal failure (AOR 2.57, 95% CI 1.02–6.48, p = 0.045), and SCCmec type II (AOR 2.60, 95%
CI 1.01–6.75, p = 0.049) were independently associated with MRSA bacteremic septic shock.
Conclusions: The development of septic shock associated with MRSA bacteremia was independently
correlated with baseline severity of illness, presence of acute renal failure, and an MRSA genotyping
consistent with nosocomially acquired MRSA infection.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Bloodstream infections (BSIs) are associated with substantial
mortality and morbidity. Staphylococcus aureus is the second
leading pathogen associated with BSIs, and the rate of methicillin
resistance is rising.1 In the most recent National Nosocomial
Infections Surveillance report, the proportion of S. aureus isolates
that showed resistance to methicillin was almost 60% among
intensive care units (ICUs) in the USA. This represents an 11%
increase when compared to resistance rates for 1998–2002.2 This
increase is methicillin resistance among S. aureus is mirrored
across the world. An even more worrisome detail is that methicillin
resistance may be an independent risk factor for adverse patient
outcome.3–6
S. aureus causes a wide range of infections.7,8 Among ICU
patients, it is the most common cause of sepsis.9 Several studies have
determined that the development of complications, including septic
shock, from S. aureus infections is correlated with increased
mortality.10,11Gomez and colleagues, in a prospective, observational* Corresponding author. Tel.: +1 216 444 8913; fax: +1 216 444 9150.
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doi:10.1016/j.ijid.2012.02.007study of all methicillin-resistant S. aureus (MRSA) bacteremia at
their institution from 2000 to 2004, found that baseline severity of
illness, inadequate empiric treatment, and the development of
complications (septic shock, acute renal failure, disseminated
intravascular coagulopathy) were independent predictors of mor-
tality.10 Furthermore, Guilarde and colleagues found severe sepsis
and septic shock to be independent risk factors for mortality among
patients with S. aureus bacteremia.11
Despite the prevalence of MRSA infections, the wide spectrum
of disease presentation, and the relationship between septic
complications and worsened outcomes, there is a paucity of data
for identifying signiﬁcant risk factors for the development of septic
shock among patients with MRSA BSI. Identifying such risk factors
may further help clinicians on the triage of patients and in the
identiﬁcation of high-risk groups for further investigation.
The aim of the present study was to determine the independent
pathogen and patient risk factors for the development of septic
shock in patients with MRSA bacteremia. Since the development of
shock in an infected patient can be affected by the initial treatment
course, including the selection of antibiotics and adequate
resuscitation, for the purposes of this study only shock that was
present at the time the ﬁrst positive blood culture was drawn was








Male, n (%) 19 (50) 124 (63) 0.13
Age, years, mean  SD 59.7  15.1 57.3  16.2 0.39
APACHE II, mean  SD 16.1  5.9 12.1  5.1 <0.001
Mode of acquisition, n (%) 0.20
Community 3 (8) 37 (19)
Nosocomial 16 (42) 63 (32)
Healthcare-associated 19 (50) 96 (49)
Co-morbidities, n (%)
Diabetes 18 (47) 82 (42) 0.53
CHF 9 (24) 44 (22) 0.87
Class III–V CKD 13 (34) 38 (19) 0.04
Immunosuppression 5 (13) 47 (24) 0.20
Source, n (%)
Respiratory 8 (21) 21 (11) 0.07
Catheter-related 11 (29) 60 (31) 0.84
Unknown 10 (26) 32 (16) 0.14
Other/mixed 9 (24) 83 (42)
MRSA genotype, n (%)
SCCmec type II 30 (79) 69 (35) 0.04
SCCmec type IV 7 (18) 123 (63) 0.04
Other 1 (3) 4 (2)
Vancomycin MIC, n (%)
1.0 mg/l 2 (5) 9 (5) 0.70
1.5 mg/l 19 (50) 108 (55) 0.56
2.0 mg/l 17 (45) 79 (40) 0.61
Additional complications, n (%)
Acute renal failure 12 (32) 20 (10) <0.001
Respiratory failure 13 (34) 27 (14) 0.002
APACHE, acute physiology and chronic health evaluation; CHF, congestive heart
failure; CKD, chronic kidney disease; MIC, minimum inhibitory concentration;
MRSA, methicillin-resistant Staphylococcus aureus; SCCmec, staphylococcal cassette
chromosome; SD, standard deviation.
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the native pathogen and patient risk factors.
2. Methods
2.1. Patient selection
The study was conducted at a large, academic, tertiary medical
care center. This was a retrospective case-controlled study of
patients with MRSA bacteremia from January 2004 to October
2006. All patients with MRSA bacteremia who received treatment
and had a hospital length of stay of at least 5 days were eligible for
inclusion. Patients with polymicrobial blood cultures and those
treated for <72 h were excluded. Only the ﬁrst episode of MRSA
bacteremia for each patient was included in the study. A
computerized list of potentially eligible patients with MRSA
bacteremia was generated by the medical informatics department
through query of the microbiology laboratory database. Data,
including demographics, clinical characteristics, and treatment,
were collected retrospectively from the patient medical records
and the pharmacy and microbiology databases. This study was
approved by the local investigational review board.
2.2. Deﬁnitions
MRSA bacteremia was deﬁned according to the Centers for
Disease Control and Prevention criteria.12 Bacteremia was deﬁned
as community-acquired, healthcare-associated, or hospital-ac-
quired according to standard deﬁnitions.13 The source of bacter-
emia was identiﬁed based on the presence of local signs and
symptoms that were temporally related (<48–72 h), in conjunc-
tion with isolation of MRSA from the implicated source before or
after MRSA blood cultures, without any other identiﬁable source.14
Potential sources of infection included intravenous catheter,
endocarditis, endovascular, respiratory, soft tissue, joints, urinary
tract, or peritoneal. Uncomplicated bacteremia was deﬁned as
isolation of MRSA from blood cultures in patients without
endocarditis and without evidence of hematogenous spread.
Complicated bacteremia was deﬁned as the presence of spread
of infection, or infection involving a prosthesis that was not
removed within 4 days.15 Septic shock was deﬁned as hemody-
namic instability with two systemic inﬂammatory response
syndrome (SIRS) criteria.16 For the purpose of identifying
independent risk factors and to avoid interference from clinician
management of severe infections, only septic shock at presentation
(at the time the culture was drawn) was considered.
2.3. Microbiological data
The local microbiology laboratory obtained vancomycin mini-
mum inhibitor concentrations (MICs) using the E-test method in
accordance with the guidelines established by the Clinical and
Laboratory Standards Institute. The staphylococcal cassette
chromosome (SCCmec) type was identiﬁed by a multiplex PCR
with four primer-pairs as previously described.17 Characterization
of Panton–Valentine leukocidin (PVL) production by S. aureus was
performed as previously described.18 The presence of PVL toxin
was evaluated in patients with SCCmec type IV MRSA bacteremia.
2.4. Statistical analysis
All comparisons were unpaired, and all tests of signiﬁcance were
two-tailed. Continuous variables were compared using the Student’s
t-test for normally distributed variables and the Mann–Whitney U-
test for non-normally distributed variables. The Chi-square test or
Fisher’s exact test was used to compare categorical variables. Amultiple logistic regression analysis was performed incorporating
potential risk factors based on statistical ﬁndings (p < 0.1) found in
the univariate analysis with plausible clinical signiﬁcance. Statistical
covariates were removed from the ﬁnal model. A statistical software
program (SPSS, version 15.0 for Windows; SPSS, Inc., Chicago, IL,
USA) was used to perform all analyses.
3. Results
3.1. Patient characteristics
Of 357 total evaluated patients, 234 were eligible and included
in the analysis. At the time the positive blood culture was drawn 38
patients (16%) were in septic shock.
The majority of the bacteremia cases were either healthcare-
associated or nosocomially acquired (83%). No difference was
found in mode of acquisition between septic shock patients and
non-septic shock patients. Patients with septic shock were more
likely to have a respiratory infection as the source of the MRSA
bacteremia, but this difference was not statistically signiﬁcant. In
addition, patients with septic shock had a higher baseline APACHE
II score and were more likely to have baseline class III–V chronic
kidney disease (CKD). Aside from the differences listed above, the
patients were matched in other evaluated areas, including age,
gender, and baseline co-morbidities (Table 1).
Interestingly, the proportion of MRSA bacteremia that caused
septic shock decreased in a step-wise fashion from 2004 to 2006,
although this trend did not reach statistical signiﬁcance (Figure 1).
3.2. Pathogen characteristics
The median E-test MIC of vancomycin for these MRSA isolates
was 1.5 mg/l. No correlation was found between vancomycin MIC
and the development of septic shock in these patients. The
Figure 1. Proportion of MRSA-induced septic shock according to year of acquisition.
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type IV MRSA, of whom 56 (74%) tested positive. Among those with
PVL-positive MRSA, only ﬁve (9%) presented with septic shock, and
no signiﬁcant association was found.
Genotyping of the MRSA species revealed that the majority
contained either SCCmec type II or type IV. A signiﬁcantly higher
proportion of patients with SCCmec type II MRSA developed septic
shock (Table 1). More of SCCmec type II isolates (92%) were either
nosocomially acquired or healthcare-associated when compared
to SCCmec type IV (p < 0.001). Eight patients who did not have
SCCmec type II developed septic shock, and of these cases seven
(88%) were either nosocomially acquired or healthcare-associated.
3.3. Outcomes
Not surprisingly, patients who presented with septic shock at
the time the ﬁrst positive culture was obtained had signiﬁcantly
higher hospital mortality (44.7% vs. 12.2%, p < 0.001). Patients
with septic shock were also more likely to have additional organ
dysfunction, including acute renal failure and respiratory failure
requiring mechanical ventilation.
3.4. Independent risk factors for septic shock
On multivariate analysis, which included all factors that met
statistical criteria and were clinically relevant, three independent
risk factors for the development of septic shock in patients with
MRSA bacteremia were found; these were increased APACHE II
score, accompanying acute renal failure, and SCCmec type II (Table
2).
4. Discussion
This study found that higher baseline APACHE II scores, acute
renal failure, and SCCmec type II containing MRSA were signiﬁcant
predictors of septic shock in patients with MRSA bacteremia. Aside
from septic shock being a signiﬁcant predictor of worsening
mortality,10,19 there were several other reasons why this outcome
measure was chosen. The majority of the studies in this area have
focused on using patient and pathogen characteristics to predict
patient outcome measures.10,11,19 However, patient outcomes may
be affected by many extraneous factors, such as institutional
standards for the management of septic shock and localTable 2
Multivariate analysis for risk of developing septic shock
Factor AOR (95% CI) p-Value
APACHE II (per point increase) 1.13 (1.04–1.22) 0.005
Acute renal failure 2.57 (1.02–6.48) 0.045
SCCmec type II 2.60 (1.01–6.75) 0.049
AOR, adjusted odds ratio; CI, conﬁdence interval; APACHE, acute physiology and
chronic health evaluation; SCCmec, staphylococcal cassette chromosome.antimicrobial utilization, dosing, and monitoring practices. Using
septic shock at the time the ﬁrst positive culture was drawn
circumvents any treatment-related biases that may otherwise be
introduced. This may partly explain why our study, unlike other
investigations,20–22 did not ﬁnd a correlation between vancomycin
MIC and outcomes. The ﬁndings of increased APACHE II score and
acute renal failure as predictors of septic shock are most likely
correlated with the baseline severity of the infection.
S. aureus causes a wide magnitude of infections. Many different
host and pathogen factors have been implicated in the severity of S.
aureus infections.23 Our study found that among patients with
MRSA bacteremia, those infected with SCCmec type II MRSA were
more likely to have septic shock. Healthcare-associated MRSA
infections are generally caused by MRSA isolates that contain
SCCmec types I, II, and III, while community-associated MRSA
isolates frequently carry SCCmec types IV or V.24–26 An interna-
tional trial that examined the distribution of resistance determi-
nants in 117 community-acquired MRSA infections, found that all
of the species had methicillin resistance by SCCmec type IV
elements.24 Studies within the past decade on the emergence of
community-acquired MRSA infections have determined that the
isolates are distinct from those that cause healthcare-associated
infections.27 Isolates from the community are susceptible to most
non-beta-lactam antibiotics,27 carry SCCmec type IV,28 and
frequently contain the PVL cytoxin.18 In contrast, MRSA strains
associated with healthcare-associated MRSA infections are usually
multidrug-resistant and carry SCCmec type II.27
Our ﬁndings are consistent with other studies that have found
worsened outcomes in patients with healthcare-acquired MRSA
infections.19,29 In a prospective observational study, Ganga and
colleagues evaluated the relationship between SCCmec type and
outcomes in patients with S. aureus bacteremia at their institu-
tion.19 On multivariate analysis, they discovered that SCCmec type
II was an independent predictor of mortality (odds ratio (OR) 3.73,
95% conﬁdence interval (CI) 1.81–7.66, p = 0.00). The authors
suggested that a possible explanation for the increased mortality
was differences in virulence factors or antibiotic susceptibility.
Since our study evaluated risk factors for septic shock at the time
the culture was drawn, it is unlikely that antibiotic susceptibility
would have been the contributing factor. This would suggest that
there may be other virulence factors that are determinants of
increased mortality with SCCmec type II infection.
Our study has a number of limitations. The epidemiological
breakdown of various subtypes of MRSA is different in different
geographical areas. Hence, the ﬁndings of SCCmec type being a
signiﬁcant predictor of septic shock may not be applicable in other
areas. However, a recent epidemiological study of invasive MRSA
infections in nine different metropolitan areas within the USA
found similar MRSA infection trends as in the current study. In that
study, 58.4% of the invasive MRSA infections were healthcare-
associated, with 26.6% and 13.4% being hospital-acquired and
community-associated, respectively.30 These proportions were
similar to those of the current study, suggesting that our local
MRSA epidemiology is similar to national trends.
In our study, the PVL toxin was assessed only in patients with
SCCmec type IV MRSA bacteremia, which precludes any conclu-
sions about the potential virulence factors in patients with SCCmec
type II infections. In addition, the retrospective nature of this study
limited the number of potential variables that could be collected. It
is conceivable that there are other confounding factors that were
not elucidated from the current study design.
Despite the known limitations of this study, our ﬁndings
suggest that there may be underlying pathogen-speciﬁc risk
factors that may predict the severity of MRSA infection. Further
research into the clinical utility of identifying pathogen risk factors
for severe infection is needed.
S.W. Lam et al. / International Journal of Infectious Diseases 16 (2012) e453–e456e456In conclusion, this study found that increased APACHE II score,
concomitant acute renal failure, and SCCmec type II genotyping
were independent risk factors for the development of septic shock
associated with MRSA bacteremia. Increased APACHE II score and
acute renal failure are most likely correlated with the severity of
baseline infection. The ﬁnding of the presence of SCCmec type II as
an independent risk factor warrants further investigation to
elucidate the potential virulence factors associated with this
genotype.
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